Additionally, being already known that in NSCLC the tumor expression of PD-L1 represents a parameter for eligibility to such drugs, we have assessed it also in the cervical tumor sample and we found a hyperexpression in both cancers (>50% in NSCLC sample and about 30% in cervical cancer). The gene discussed is CD274; the disease is non-small cell lung carcinoma.